Skip to main content

Table 4 ANOVA analysis comparing patients with and without recieving durvalumab maintenance therapy regarding LDH, hemoglobin, leukocytes, thrombocytes, GOT, GPT and albumin

From: Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

Parameter

Baseline

Begin Durvalumab

3 months FU

6 months FU

9 months FU

12 months FU

p-value

p-value

p-value

p-value

p-value

p-value

LDH

0.784

0.440

0.349

0.589

0.965

0.537

Hemoglobin

0.774

0.530

0.196

0.222

0.015

0.115

Leukocytes

0.528

0.413

0.882

0.778

0.336

0.762

Thrombocytes

0.294

0.835

0.749

0.929

0.757

0.122

GOT

0.724

0.053

0.421

0.883

0.949

0.827

GPT

0.291

0.096

0.060

0.048

0.199

0.284

Albumin

0.538

0.116

0.967

0.304

0.164

0.195

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us